Travere Therapeutics (TVTX) Retained Earnings (2011 - 2026)

Travere Therapeutics has reported Retained Earnings for 16 years, with the latest figure at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 25.98% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$1.1 million (down 25.98% YoY), and the FY2025 full-year result was -$1.5 billion, down 1840791.25% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.1 million, up from -$1.5 billion in the prior quarter.
• The five-year high for Retained Earnings was $303000.0 in Q3 2022, with the low at -$1.5 billion in Q3 2025.
• Historically, Retained Earnings has averaged -$646.6 million across 5 years, with a median of -$811.7 million in 2022.
• Annual changes were most pronounced in 2022 — Retained Earnings soared 100.04% — and 2025, when it sank 1840791.25%.
• Travere Therapeutics' Retained Earnings stood at -$1.0 billion in 2022, then decreased by 10.98% to -$1.1 billion in 2023, then surged by 99.99% to -$80000.0 in 2024, then slumped by 1840791.25% to -$1.5 billion in 2025, then soared by 99.93% to -$1.1 million in 2026.
• The last three Retained Earnings figures came in at -$1.1 million (Q1 2026), -$1.5 billion (Q4 2025), and -$1.5 billion (Q3 2025), per Business Quant data.